The aim of the project is to develop a new generation of DIANA Biotech platform for development of monoclonal antibodies. The project will result in a set of methods and procedures which will upgrade the key steps in monoclonal antibody development in DIANA Biotechnologies. In addition, a set of commercially applicable recombinant monoclonal antibodies will be developed, covering a spectrum of difficult targets (small molecules of Kratom alkaloids and synthetic opioids, trans-membrane proteins).

The project is implemented with University of Chemistry and Technology, Forensic Laboratory of Biologically Active Substances.

The project aims to increase exports of DIANA Biotechnologies through participation at international exhibitions and fairs. The participation at international events will contribute to promotion of our products and services and will help the company to establish contacts with new customers and distributors.

The aim of the projects is to develop PCR methods and diagnostic sets for rapid and sensitive detection of the most frequent pathogens causing sepsis. The envisaged outputs seek to transform the current standards in the diagnosis of sepsis allowing for faster, cheaper and more reliable diagnosis of sepsis.

The project is implemented in collaboration with Palacky University Olomouc (University Hospital Olomouc) and Motol University Hospital.

This project was funded under the National Recovery Plan from the European Recovery and Resilience Facility.

The project aims to verify technical feasibility of a PCR method for detection of somatic mutations. If successful, the method could find many potential applications in cancer diagnostic and patient profiling. In addition, the feasibility study intends to verify the commercial viability of such method both in terms of market potential and in terms of clinical validation and regulatory requirements.

The co-funded by the EU through the Operational Program Technologies and Application for Competitiveness (call: Proof of Concept II.).

The aim of the project is to develop DIANA method for measuring selectivity and potency of CDK inhibitors and to identify new potential inhibitors of CDK11 for further clinical development.

The outputs of the project include groundbreaking tools revolutionizing the field of kinase inhibitor profiling DIANA CDK Panel and DIANA Kinase Panel. More information about the project outputs is available in the drug discovery section of DIANA Biotechnologies website.

The project is implemented in collaboration with Masaryk University in Brno (CEITEC, Faculty of Science).

The aim of the project is to develop DIANA Biotech PCR cycler from pre-series build to first pilot series.

The aim of the project is innovation of digital tool for product development and business support services of DIANA Biotechnologies.

The aim of this project is the development and validation of in vitro ADME assays based on DIANA technology.

The aim of the project is to develop sets for RNA isolation, RT-PCR detection and protocol for implementation of automatic COVID-19 testing.

The project is cofinanced through the programme Czech Rise Up – Smart solutions for COVID-19.